Elutia Inc (ELUT) Hedge Fund & Institutional Holdings (Q2 2026)

Elutia Inc. (ticker: ELUT) closed the sale of its SimpliDerm business to Cellution Biologics on August 17, 2026, following the asset purchase agreement the two parties signed back on July 16. The business — making and selling human acellular dermis (hADM) products used in breast reconstruction under the SimpliDerm brand — accounted for substantially all of the assets of Elutia's Women's Health segment. Elutia received $7.7 million at closing, with the purchase price still subject to a post-closing inventory valuation adjustment and up to another $3 million in contingent payments over the next 18 months tied to technology transfer and commercial milestones. As part of the deal, Elutia also agreed to a five-year non-compete in related hADM lines, will provide up to six months of transition services, and amended its loan agreement to release the lien on the sold assets.

AI summary pending

Elutia Inc. said on Aug. 6, 2026 that Nasdaq told it its Class A common stock has closed below $1.00 for 30 straight business days, breaking the minimum bid price rule for continued listing. The stock still trades on the Nasdaq Capital Market as "ELUT" for now, and the company has 180 days — until Feb. 2, 2027 — to fix this by closing at $1.00 or higher for at least 10 consecutive days. If it misses that window, it might be eligible for another 180 days, or it could face delisting.

AI summary pending